New drug combo shows promise for tough leukemia
NCT ID NCT03009240
First seen Apr 23, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This early-stage study tested two drugs, pevonedistat and decitabine, together in 12 people with high-risk acute myeloid leukemia (AML). The main goal was to find the safest dose and understand side effects. The drugs work by blocking enzymes that cancer cells need to grow. This study did not aim to cure the disease, but to control it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.